Breast Implant-Associated Cancers — Austin, TX
Two rare but serious cancers are associated with breast implants: BIA-ALCL and BIA-SCC. Both arise within the scar tissue capsule surrounding the implant. Both are treated with en bloc capsulectomy — and surgical outcome depends directly on whether that procedure is performed correctly.
Dr. Robert Whitfield MD, FACS • Austin, Texas • 1,000+ Explant Procedures
What Are Breast Implant-Associated Cancers?
The U.S. FDA has identified two distinct cancers that can develop in the tissue surrounding breast implants:
| Cancer | Type | Primary Location | Implant Association |
|---|---|---|---|
| BIA-ALCL | T-cell lymphoma (immune system cancer) | Fluid surrounding implant; capsule tissue | Textured implants — especially macro-textured surfaces |
| BIA-SCC | Squamous cell carcinoma | Capsule tissue adjacent to implant | Reported across implant types; mechanism under investigation |
Neither condition is breast cancer in the conventional sense. BIA-ALCL is a lymphoma — a cancer of the immune system — and BIA-SCC is a carcinoma arising in the squamous cells of the capsule. Both are distinct from the breast cancer that develops in breast glandular tissue.
Both conditions are rare. Both are serious. Both are treated with en bloc capsulectomy — complete, intact removal of the implant and surrounding capsule as one sealed unit — which is the FDA-endorsed, NCCN-recommended surgical standard for BIA-ALCL and the emerging standard for BIA-SCC.
Breast Implant-Associated Anaplastic Large Cell Lymphoma
What Is BIA-ALCL?
BIA-ALCL is a cancer of the T-cells of the immune system. It develops in the fluid that accumulates between the breast implant and the surrounding scar tissue capsule, or within the capsule tissue itself. It is categorized as a type of non-Hodgkin lymphoma. When diagnosed at a localized stage and treated with complete en bloc capsulectomy, surgical cure is achievable in the majority of cases.
Risk Factors
| Risk Factor | Detail |
|---|---|
| Implant surface texture | Textured implants — especially macro-textured (BIOCELL) — carry the highest documented risk |
| Smooth implants | Rarely implicated; predominantly a textured implant disease |
| Implant fill type | Reported with both silicone and saline textured implants |
| Implant age at diagnosis | Median presentation approximately 7–10 years after placement |
| Prior BIA-ALCL | Incomplete surgical removal is the primary driver of recurrence |
Signs and Symptoms
The most common early symptom is late seroma — a fluid collection developing around the implant more than one year after placement, without an obvious cause such as injury or infection.
- ✓Late seroma — swelling or fluid accumulation developing years after placement
- ✓Breast enlargement or asymmetry not explained by weight change
- ✓Breast firmness or a new palpable mass near the implant
- ✓Skin changes, rash, or thickening around the breast
- ✓Swollen lymph nodes in the axilla (armpit)
BIA-ALCL Staging
| Stage | Disease Location | Surgical Approach |
|---|---|---|
| IA | Fluid only — no capsule involvement, no mass | En bloc capsulectomy; surgical cure in most cases |
| IB | Capsule involvement, no mass, no lymph node spread | En bloc capsulectomy; potentially curative |
| IC | Capsule involvement with mass confined to capsule | En bloc capsulectomy + mass excision |
| II | Regional lymph node involvement | En bloc + lymph node surgery ± systemic therapy |
| III/IV | Spread beyond regional nodes | Systemic chemotherapy; surgery determined by oncology team |
Breast Implant-Associated Squamous Cell Carcinoma (BIA-SCC)
BIA-SCC is a carcinoma arising in the squamous cells of the capsule tissue surrounding a breast implant. The FDA issued a safety communication on BIA-SCC in September 2022. Unlike BIA-ALCL, the implant types involved include a broader range of surfaces.
BIA-SCC is significantly rarer than BIA-ALCL — fewer than 30 cases had been reported globally at the time of the FDA’s 2022 safety communication. Several reported cases had aggressive clinical behavior.
Any late seroma or unexplained capsule change warrants complete pathological evaluation regardless of which implant-associated cancer is suspected.
En Bloc Capsulectomy as the Standard of Care
For both BIA-ALCL and BIA-SCC, the surgical treatment is en bloc capsulectomy — complete, intact removal of the implant and surrounding capsule as one sealed unit, without opening or disrupting the capsule during surgery.
| Surgical Approach | Oncologic Adequacy |
|---|---|
| Simple implant removal (capsule left in place) | Unacceptable — leaves the primary tumor site entirely |
| Total capsulectomy (capsule removed in pieces) | Insufficient — does not meet NCCN oncologic standards |
| En bloc capsulectomy (capsule never opened) | FDA-endorsed and NCCN-recommended standard |
What Complete En Bloc Resection Requires
Pre-operative planning — MRI or ultrasound to map fluid, masses, and capsule extent
Circumferential dissection — entire capsule freed without entering it
Intact removal — implant, fluid, and capsule removed as one specimen
Intraoperative containment — fluid does not contact the surgical field
Pathological analysis — reviewed by hematopathologist experienced with BIA-ALCL
Documentation of surgical margins — complete excision confirmed
PCR Pathology on Every Specimen
Every capsule removed at Dr. Whitfield’s practice is sent for PCR-based molecular pathology — 16S rRNA gene sequencing. In Dr. Whitfield’s published research, 29% of 694 consecutive capsule specimens tested positive for bacterial contamination, with 103 distinct bacterial species identified. Standard culture testing detected none.
Why Choose Dr. Whitfield for Breast Implant-Associated Cancer Surgery
| Credential | Detail |
|---|---|
| Board Certification | American Board of Plastic Surgery, FACS |
| Explant procedures | 1,000+ — including en bloc for confirmed and suspected BIA-ALCL |
| PCR capsule research | Largest series in medical literature — 694 specimens, 103 bacterial species, 29% contamination |
| FDA testimony | Testified before the U.S. General and Plastic Surgery Devices Panel |
| En bloc capsulectomy | Standard technique for all oncologic indications |
| Patients served | 40+ states and 15 countries |
Frequently Asked Questions About Breast Implant-Associated Cancers
What is BIA-ALCL?
+
BIA-ALCL stands for Breast Implant-Associated Anaplastic Large Cell Lymphoma. It is a rare type of T-cell lymphoma that can develop in the scar tissue and fluid surrounding a breast implant. It is not breast cancer, but rather a cancer of the immune system.
What are the symptoms of BIA-ALCL?
+
The most common symptom is a persistent swelling or pain in the vicinity of the breast implant, often developing years after the initial surgery. Other signs can include a lump in the breast or armpit, or skin rash. Any new changes around your implants should be evaluated by a physician.
Are some implants higher risk for BIA-ALCL?
+
Yes, the risk of BIA-ALCL is most strongly associated with textured-surface breast implants. The FDA has requested the recall of certain textured implants due to this association. However, it has been reported in all implant types, so ongoing vigilance is important for all patients.
What is BIA-SCC?
+
BIA-SCC, or Breast Implant-Associated Squamous Cell Carcinoma, is another rare but aggressive cancer that can arise in the capsule around breast implants. Unlike BIA-ALCL, it is an epithelial-based tumor. The FDA has issued safety communications to raise awareness of this potential risk.
How are breast implant-associated cancers diagnosed?
+
Diagnosis typically involves imaging (like an ultrasound or MRI) to assess fluid collection or masses, followed by a biopsy. For suspected BIA-ALCL, the fluid and capsule tissue must be tested for a specific marker called CD30 to confirm the diagnosis.
What is the treatment for BIA-ALCL?
+
When caught early and confined to the capsule, the standard treatment for BIA-ALCL is surgery to remove the implant and the entire capsule (en bloc or total capsulectomy). In more advanced cases, chemotherapy and radiation may be necessary.
Should I have my implants removed to prevent cancer?
+
This is a personal decision that should be made in consultation with a board-certified plastic surgeon. While the absolute risk is low, if you are concerned about BIA-ALCL or BIA-SCC, discussing the risks and benefits of explant surgery is a reasonable step.
How can I monitor for these cancers?
+
Regular self-exams and routine follow-up with your plastic surgeon are important. If you have textured implants, the FDA recommends periodic screening. Any new or unusual symptoms, such as swelling, pain, or lumps, should be promptly reported to your doctor for evaluation.
Next Steps
If you have textured breast implants and are experiencing late seroma, unexplained breast asymmetry, or any new breast changes — prompt evaluation is appropriate. Virtual consultations are available for patients outside Austin.
You Deserve a Surgeon Who Prepares You, Not Just Operates on You.
Dr. Robert Whitfield has guided thousands of patients through surgical decisions with clarity, data, and a personalized plan. Your consultation is where that plan begins.
Not ready to book? Download the free Inflammation Support Guide to start your journey.